Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $39.7900 (2.63%) ($39.7900 - $39.7900) on Fri. Jun. 25, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.93% (three month average) | RSI | 67 | Latest Price | $39.7900(2.63%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.2% a day on average for past five trading days. | Weekly Trend | TGTX advances 1.2% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) IBB(59%) IWO(59%) ARKK(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.465% in a week (0% probabilities). VIXM(-45%) VXX(-38%) UUP(-18%) UNG(-3%) TLT(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.465% (StdDev 2.93%) | Hourly BBV | 1.6 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $38.31(3.86%) | 10 Day Moving Average | $37.96(4.82%) | 20 Day Moving Average | $37.07(7.34%) | To recent high | -18.3% | To recent low | 22.7% | Market Cap | $5.039b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |